BioAge Labs Q1 net loss $22.3M; positive Phase 1 data for BGE-102 NLRP3 inhibitor

BioAge Labs, Inc.

2026-Q1 EPS reported -$0.52 revenue$2,772,000

Net loss $22.3M ($0.52 diluted EPS) vs $12.9M ($0.36) in Q1 2025; R&D spend rose to $20.4M.
Positive Phase 1 data for oral NLRP3 inhibitor BGE-102: median hsCRP reduction 86%, 87-93% reached normalized hsCRP <2 mg/L.
Ph2 dose-ranging trial in CVD risk and Ph1b/2a in diabetic macular edema both planned to start mid-2026.
Cash, equivalents & securities $384.9M as of Mar 31, 2026; funded through 2029.
Completed upsized follow-on offering for $132.3M in gross proceeds in early 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

BioAge Labs, Inc. reported first quarter ended March 31, 2026 results: revenue 2.8 million, net income -22.3 million, EPS -0.52.

Period: first quarter ended March 31, 2026
Revenue: 2.8 million
Net income: -22.3 million
EPS: -0.52
Result: reported results

Exact text from the filing

with Lilly ExploR&D for the development of therapeutic antibodies targeting novel metabolic aging targets. First Quarter 2026 Financial Results Collaboration revenue was $2.8 million for the quarter ended March 31, 2026, compared to $1.5 million for the same period in 2025. The $1.3 million increase in collaboration revenue was due to increased full-time

View on SEC.gov

Browse all earnings releases →

BioAge Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-213472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.